Castle Biosciences (CSTL) Revenue (2018 - 2026)

Castle Biosciences has disclosed Revenue across 9 years of filings, most recently posting $83.7 million for Q1 2026.

• Revenue for Q1 2026 came in at $83.7 million, down 4.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $339.9 million (down 2.06% YoY), and the FY2025 annual result was $344.2 million, up 3.66% from the prior year.
• Revenue came in at $83.7 million for Q1 2026 at Castle Biosciences, down from $87.0 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $88.0 million in Q1 2025 to a low of $26.9 million in Q1 2022.
• The 5-year median for Revenue is $73.0 million (2024), against an average of $65.7 million.
• Across the five-year window, Revenue jumped 73.59% in 2024 and fell 4.9% in 2026, its largest moves.
• Castle Biosciences' Revenue stood at $38.3 million in 2022, then surged by 72.47% to $66.1 million in 2023, then jumped by 30.54% to $86.3 million in 2024, then rose by 0.81% to $87.0 million in 2025, then decreased by 3.83% to $83.7 million in 2026.
• The last three Revenue figures came in at $83.7 million (Q1 2026), $87.0 million (Q4 2025), and $83.0 million (Q3 2025), per Business Quant data.